Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EPS (Weighted Average and Diluted): 2013-2023

Historic EPS (Weighted Average and Diluted) for RedHill Biopharma (RDHL) over the last 1 years, with Jun 2023 value amounting to $46.11.

  • RedHill Biopharma's EPS (Weighted Average and Diluted) rose 56144.35% to $46.11 in Q2 2023 from the same period last year, while for Jun 2023 it was $46.01, marking a year-over-year increase of 2402252.13%. This contributed to the annual value of $0.01 for FY2023, which is 108.33% up from last year.
  • As of Q2 2023, RedHill Biopharma's EPS (Weighted Average and Diluted) stood at $46.11, which was up 137,093.02% from -$0.03 recorded in Q3 2022.
  • In the past 5 years, RedHill Biopharma's EPS (Weighted Average and Diluted) registered a high of $46.11 during Q2 2023, and its lowest value of -$0.08 during Q2 2022.
  • Its 3-year average for EPS (Weighted Average and Diluted) is $7.68, with a median of $0.03 in 2021.
  • As far as peak fluctuations go, RedHill Biopharma's EPS (Weighted Average and Diluted) crashed by 217.44% in 2022, and later spiked by 56,144.35% in 2023.
  • Quarterly analysis of 5 years shows RedHill Biopharma's EPS (Weighted Average and Diluted) stood at $0.03 in 2019, then surged by 54.62% to $0.05 in 2020, then slumped by 32.91% to $0.03 in 2021, then plummeted by 217.44% to -$0.03 in 2022, then skyrocketed by 56,144.35% to $46.11 in 2023.
  • Its EPS (Weighted Average and Diluted) was $46.11 in Q2 2023, compared to -$0.03 in Q3 2022 and -$0.08 in Q2 2022.